Determinants of pancreatic tropism in metastatic renal cell carcinoma
Authors:
- Haitao XuHXHaitao Xu
- Payal KapurPKPayal Kapur
- Alana ChristieACAlana Christie
- Aleksandra W. NielsenANAleksandra W. Nielsen
- Averi PernyAPAveri Perny
- Olivia BrandenburgOBOlivia Brandenburg
- Charlotte SmallCSCharlotte Small
- Jeffrey MiyataJMJeffrey Miyata
- Hua ZhongHZHua Zhong
- Courtney RobertsCRCourtney Roberts
- Roy EliasRERoy Elias
Open Access
- 27 January 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (5)
Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) with pancreatic metastases (PM) is paradoxically associated with prolonged overall survival (OS), but the biological basis for this observation remains unclear. METHODS: We analyzed matched primary and metastatic samples from an international consortium of patients with PM ( n = 108) and compared them with a previously characterized ccRCC cohort without PM ( n = 273). RESULTS: Primary ccRCC tumors associated with PM were dominated by indolent, angiogenic phenotypes, characterized by low-grade histology and reduced mTORC1 activation (all P < 0.001). Tumors of patients with PM were often PBRM1-deficient (80.4% vs. 54.8%, P < 0.001) and rarely harbored BAP1 loss (3.7% vs. 20.7%, P < 0.001). After metastasis diagnosis, patients with PM had significantly longer median OS compared with those without PM (110 vs. 33 months, HR 0.28 [95% CI, 0.19–0.39], P < 0.001). Survival was further prolonged among patients with PBRM1 loss (143 vs. 64 months, HR 0.41 [95% CI, 0.22–0.81], P = 0.008). Notably, PM lesions were typically low-grade and PBRM1-deficient even when more aggressive and evolved clones were present in primary tumors. Finally, PBRM1 loss was associated with preferential response to angiogenesis inhibitors over immune-oncology therapy, reflected by longer time on treatment (32.1 vs. 9.1 months, HR 0.16 [95% CI, 0.06–0.39], P < 0.001). CONCLUSION: These findings illustrate selective tropism of indolent, less-evolved, PBRM1-deficient ccRCC clones for pancreatic dissemination. This biological bias likely underlies therapeutic sensitivity and favorable survival, supporting the consideration of PBRM1 status and metastatic tropism in risk stratification and treatment selection. FUNDING: NIH Kidney Cancer SPORE grant (P50CA196516); The Cancer Prevention and Research Institute of Texas (RP220294); Endowment from Jan and Bob Pickens Distinguished Professorship in Medical Science and Brock Fund for Medical Science Chair in Pathology.Keywords
Funding Information
- Instituto Nacional de Cancerología (P50CA196516)
This publication has 56 references indexed in Scilit:
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialAnnals of Oncology, 2024
- Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic TherapyClinical Genitourinary Cancer, 2021
- Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalJAMA Network Open, 2021
- The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer ParadigmCancer Cell, 2020
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeCancer Cell, 2020
- Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell CarcinomaClinical Genitourinary Cancer, 2018
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalCell, 2018
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell, 2018
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Prognostic relevance of the mTOR pathway in renal cell carcinomaCancer, 2007